Cancer Management and Research (Nov 2020)
Biomolecular Factors Represented by Bcl-2, p53, and Tumor-Infiltrating Lymphocytes Predict Response for Adjuvant Anthracycline Chemotherapy in Patients with Early Triple-Negative Breast Cancer
Abstract
Xenia Elena Bacinschi,1,2 Anca Zgura,2 Inga Safta,3 Rodica Anghel1,2 1Department of Oncology-Radiotherapy, Institute of Oncology Prof. Dr. Alexandru Trestioreanu, Bucharest, Romania; 2University of Medicine and Pharmacy Carol Davila, Bucharest, Romania; 3Department of Medical Oncology, Antoine Lacassagne Cancer Center, Nice, FranceCorrespondence: Anca ZguraUniversity of Medicine and Pharmacy Carol Davila, 8 Eroii Sanitari Blvd., Bucharest 050474, RomaniaEmail [email protected]: Treatment of triple-negative breast cancer is challenging. Standard adjuvant tretment is considered to be the cobination of anthracycline and taxanes although the role of anthracyclines administered preoperatively remains controversial. Actually, some studies recommended taxane-only regimens. We reviewed literatures to examine whether tissue biomarkers available in an ordinary laboratory setting (eg, haematoxylin and eosin and immunohistochemistry) may predict response to adjuvant anthracyclines in patients with triple-negative breast cancer. Our review showed that Bcl-2, p53, and tumor-infiltrating lymphocytes (TILs) expression may become independent predictors for triple-negative breast cancer. This finding was based on data from retrospective studies, and, thus, randomized controlled study is needed to confirm the present results.Keywords: anthracyclines, biological tumour markers, triple-negative breast cancer, predictive, survival, p53, Bcl-2, TILs
